表紙
市場調査レポート

転移性腎細胞癌:世界の治験レビュー

Metastatic Renal Cell Carcinoma Global Clinical Trials Review, H1, 2014

発行 GlobalData 商品コード 299728
出版日 ページ情報 英文 201 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.16円で換算しております。
Back to Top
転移性腎細胞癌:世界の治験レビュー Metastatic Renal Cell Carcinoma Global Clinical Trials Review, H1, 2014
出版日: 2014年04月15日 ページ情報: 英文 201 Pages
概要

当レポートでは、転移性腎細胞癌に関する臨床研究の最新動向について分析し、疾患・治療法の概要や、主な先進国・新興国における治験の状況、地域・フェーズ(相)・段階別の進行状況、有望なスポンサー、各企業・研究機関での研究の進行状況、有望な薬剤の比較といった情報を盛り込んで、概略以下の構成でお届けします。

目次

イントロダクション

  • 転移性腎細胞癌
  • 当レポートの概要

各地域における治験状況

  • 各国の治験件数と平均被験者数
    • アジア太平洋地域上位5ヶ国における治験件数
    • 欧州上位5ヶ国における治験件数
    • 北米の主要国における治験件数
    • 中東・アフリカ上位5ヶ国における治験件数
    • 中南米上位5ヶ国における治験件数

G7諸国での治験件数:腫瘍全体に対する比率

G7諸国での治験件数:フェーズ(相)別

G7諸国での治験件数:進捗状況別

E7諸国での治験件数:腫瘍全体に対する比率

E7諸国での治験件数:フェーズ(相)別

E7諸国での治験件数:進捗状況別

フェーズ(相)別の治験件数

  • 進行中の治験:フェーズ別

進捗状況別の治験件数

治験の目標の達成状況

未完了の治験件数

一定期間に採用された被験者

スポンサーの種類別の治験件数

有望なスポンサー

  • 転移性腎細胞癌治療薬の治験に参加している上位企業

有望な薬剤

治験の最新動向(全5件)

治験のプロファイル

  • 代表的企業の治験の概要
    • Pfizer Inc.
    • Novartis AG
    • Bayer AG
    • F. Hoffmann-La Roche Ltd.
    • GlaxoSmithKline plc
    • Bristol-Myers Squibb Company
    • AstraZeneca PLC
    • Eli Lilly and Company
    • iOMEDICO AG
    • Amgen Inc.
  • 代表的な研究機関・病院の治験の概要
    • National Cancer Institute
    • The University of Texas M. D. Anderson Cancer Center
    • Memorial Sloan Kettering Cancer Center
    • The University of Chicago
    • Case Comprehensive Cancer Center
    • UCLA's Jonsson Comprehensive Cancer Center
    • University of California, San Francisco
    • Radboud University
    • European Organization for Research and Treatment of Cancer
    • Roswell Park Cancer Institute

5つの代表的な治験のプロファイル

付録

図表一覧

目次
Product Code: GDHC2075CTIDB

GlobalData's clinical trial report, "Metastatic Renal Cell Carcinoma Global Clinical Trials Review, H1, 2014" provides data on the Metastatic Renal Cell Carcinoma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Metastatic Renal Cell Carcinoma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Metastatic Renal Cell Carcinoma. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
  • Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
  • Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

  • Understand the dynamics of a particular indication in a condensed manner
  • Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
  • Obtain discontinued trial listing for trials across the globe
  • Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Metastatic Renal Cell Carcinoma
    • Report Guidance
  • Clinical Trials by Region
    • Clinical Trials and Average Enrollment by Country
      • Top Five Countries Contributing to Clinical Trials in Asia-Pacific
      • Top Five Countries Contributing to Clinical Trials in Europe
      • Top Countries Contributing to Clinical Trials in North America
      • Top Five Countries Contributing to Clinical Trials in Middle East and Africa
      • Top Five Countries Contributing to Clinical Trials in Central and South America
  • Clinical Trials by G7 Countries: Proportion of Metastatic Renal Cell Carcinoma to Oncology Clinical Trials
  • Clinical Trials by Phase in G7 Countries
  • Clinical Trials in G7 Countries by Trial Status
  • Clinical Trials by E7 Countries: Proportion of Metastatic Renal Cell Carcinoma to Oncology Clinical Trials
  • Clinical Trials by Phase in E7 Countries
  • Clinical Trials in E7 Countries by Trial Status
  • Clinical Trials by Phase
    • In Progress Trials by Phase
  • Clinical Trials by Trial Status
  • Clinical Trials by End Point Status
  • Unaccomplished Trials of Metastatic Renal Cell Carcinoma
  • Subjects Recruited Over a Period of Time
  • Clinical Trials by Sponsor Type
  • Prominent Sponsors
    • Top Companies Participating in Metastatic Renal Cell Carcinoma Therapeutics Clinical Trials
  • Prominent Drugs
  • Latest Clinical Trials News on Metastatic Renal Cell Carcinoma
    • Jan 14, 2014: Rexahn Initiates Phase IIa Clinical Trial of Archexin in Patients with Metastatic Renal Cell Carcinoma
    • Dec 19, 2013: NewLink Genetics Launches Phase 1 Clinical Trial of Its HyperAcute Renal Immunotherapy in Patients With Metastatic Renal Cell Cancer
    • Oct 22, 2013: Curis and Debiopharm Announce Initiation of Phase I Dose Finding Clinical Study With a Combination of HSP90 Inhibitor Debio 0932 and Everolimus
    • Sep 24, 2013: Argos Therapeutics Announces Globalization of Pivotal Phase 3 ADAPT Study for Personalized Cancer Immunotherapy
    • Sep 23, 2013: TRACON Pharmaceuticals Initiates Phase 1b Study of TRC105 in Patients With Metastatic Renal Cell Carcinoma
  • Clinical Trial Profiles
    • Clinical Trial Overview of Top Companies
      • Pfizer Inc.
      • Clinical Trial Overview of Pfizer Inc.
      • Novartis AG
      • Clinical Trial Overview of Novartis AG
      • Bayer AG
      • Clinical Trial Overview of Bayer AG
      • F. Hoffmann-La Roche Ltd.
      • Clinical Trial Overview of F. Hoffmann-La Roche Ltd.
      • GlaxoSmithKline plc
      • Clinical Trial Overview of GlaxoSmithKline plc
      • Bristol-Myers Squibb Company
      • Clinical Trial Overview of Bristol-Myers Squibb Company
      • AstraZeneca PLC
      • Clinical Trial Overview of AstraZeneca PLC
      • Eli Lilly and Company
      • Clinical Trial Overview of Eli Lilly and Company
      • iOMEDICO AG
      • Clinical Trial Overview of iOMEDICO AG
      • Amgen Inc.
      • Clinical Trial Overview of Amgen Inc.
    • Clinical Trial Overview of Top Institutes / Government
      • National Cancer Institute
      • Clinical Trial Overview of National Cancer Institute
      • The University of Texas M. D. Anderson Cancer Center
      • Clinical Trial Overview of The University of Texas M. D. Anderson Cancer Center
      • Memorial Sloan Kettering Cancer Center
      • Clinical Trial Overview of Memorial Sloan Kettering Cancer Center
      • The University of Chicago
      • Clinical Trial Overview of The University of Chicago
      • Case Comprehensive Cancer Center
      • Clinical Trial Overview of Case Comprehensive Cancer Center
      • UCLA's Jonsson Comprehensive Cancer Center
      • Clinical Trial Overview of UCLA's Jonsson Comprehensive Cancer Center
      • University of California, San Francisco
      • Clinical Trial Overview of University of California, San Francisco
      • Radboud University
      • Clinical Trial Overview of Radboud University
      • European Organization for Research and Treatment of Cancer
      • Clinical Trial Overview of European Organization for Research and Treatment of Cancer
      • Roswell Park Cancer Institute
      • Clinical Trial Overview of Roswell Park Cancer Institute
  • Five Key Clinical Profiles
  • Appendix
    • Abbreviations
    • Definitions
    • Research Methodology
    • Secondary Research
    • About GlobalData
    • Contact Us
    • Disclaimer
    • Source

List of Tables

  • Metastatic Renal Cell Carcinoma Therapeutics, Global, Clinical Trials by Region, 2014*
  • Metastatic Renal Cell Carcinoma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014*
  • Metastatic Renal Cell Carcinoma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014*
  • Metastatic Renal Cell Carcinoma Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2014*
  • Metastatic Renal Cell Carcinoma Therapeutics Clinical Trials, Europe, Top Five Countries, 2014*
  • Metastatic Renal Cell Carcinoma Therapeutics Clinical Trials, North America, Top Countries, 2014*
  • Metastatic Renal Cell Carcinoma Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2014*
  • Metastatic Renal Cell Carcinoma Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2014*
  • Proportion of Metastatic Renal Cell Carcinoma to Oncology Clinical Trials, G7 Countries (%), 2014*
  • Metastatic Renal Cell Carcinoma Therapeutics, G7 Countries, Clinical Trials by Phase, 2014*
  • Metastatic Renal Cell Carcinoma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014*
  • Proportion of Metastatic Renal Cell Carcinoma to Oncology Clinical Trials, E7 Countries (%), 2014*
  • Metastatic Renal Cell Carcinoma Therapeutics, E7 Countries, Clinical Trials by Phase, 2014*
  • Metastatic Renal Cell Carcinoma Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014*
  • Metastatic Renal Cell Carcinoma Therapeutics, Global, Clinical Trials by Phase, 2014*
  • Metastatic Renal Cell Carcinoma Therapeutics, Global, Clinical Trials In Progress by Phase 2014*
  • Metastatic Renal Cell Carcinoma Therapeutics, Global, Clinical Trials by Trial Status, 2014*
  • Metastatic Renal Cell Carcinoma Therapeutics Clinical Trials, Global, by End Point Status, 2014*
  • Metastatic Renal Cell Carcinoma Therapeutics, Global, Suspended Clinical Trials, 2014*
  • Metastatic Renal Cell Carcinoma Therapeutics, Global, Withdrawn Clinical Trials, 2014*
  • Metastatic Renal Cell Carcinoma Therapeutics, Global, Terminated Clinical Trials, 2014*
  • Metastatic Renal Cell Carcinoma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013
  • Metastatic Renal Cell Carcinoma Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014*
  • Metastatic Renal Cell Carcinoma Therapeutics Clinical Trials, Global, Key Sponsors, 2014*
  • Metastatic Renal Cell Carcinoma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014*
  • Metastatic Renal Cell Carcinoma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014*
  • Metastatic Renal Cell Carcinoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Pfizer Inc., 2014*
  • Metastatic Renal Cell Carcinoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Novartis AG, 2014*
  • Metastatic Renal Cell Carcinoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Bayer AG, 2014*
  • Metastatic Renal Cell Carcinoma Therapeutics Clinical Trials Market, Global, Clinical Trials by F. Hoffmann-La Roche Ltd., 2014*
  • Metastatic Renal Cell Carcinoma Therapeutics Clinical Trials Market, Global, Clinical Trials by GlaxoSmithKline plc, 2014*
  • Metastatic Renal Cell Carcinoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Bristol-Myers Squibb Company, 2014*
  • Metastatic Renal Cell Carcinoma Therapeutics Clinical Trials Market, Global, Clinical Trials by AstraZeneca PLC, 2014*
  • Metastatic Renal Cell Carcinoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Eli Lilly and Company, 2014*
  • Metastatic Renal Cell Carcinoma Therapeutics Clinical Trials Market, Global, Clinical Trials by iOMEDICO AG, 2014*
  • Metastatic Renal Cell Carcinoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Amgen Inc., 2014*
  • Metastatic Renal Cell Carcinoma Therapeutics Clinical Trials Market, Global, Clinical Trials by National Cancer Institute, 2014*
  • Metastatic Renal Cell Carcinoma Therapeutics Clinical Trials Market, Global, Clinical Trials by The University of Texas M. D. Anderson Cancer Center, 2014*
  • Metastatic Renal Cell Carcinoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Memorial Sloan Kettering Cancer Center, 2014*
  • Metastatic Renal Cell Carcinoma Therapeutics Clinical Trials Market, Global, Clinical Trials by The University of Chicago, 2014*
  • Metastatic Renal Cell Carcinoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Case Comprehensive Cancer Center, 2014*
  • Metastatic Renal Cell Carcinoma Therapeutics Clinical Trials Market, Global, Clinical Trials by UCLA's Jonsson Comprehensive Cancer Center, 2014*
  • Metastatic Renal Cell Carcinoma Therapeutics Clinical Trials Market, Global, Clinical Trials by University of California, San Francisco, 2014*
  • Metastatic Renal Cell Carcinoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Radboud University, 2014*
  • Metastatic Renal Cell Carcinoma Therapeutics Clinical Trials Market, Global, Clinical Trials by European Organization for Research and Treatment of Cancer, 2014*
  • Metastatic Renal Cell Carcinoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Roswell Park Cancer Institute, 2014*

List of Figures

  • Metastatic Renal Cell Carcinoma Therapeutics, Global, Clinical Trials by Region (%), 2014*
  • Metastatic Renal Cell Carcinoma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014*
  • Metastatic Renal Cell Carcinoma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014*
  • Metastatic Renal Cell Carcinoma Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2014*
  • Metastatic Renal Cell Carcinoma Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014*
  • Metastatic Renal Cell Carcinoma Therapeutics Clinical Trials, North America, Top Countries (%), 2014*
  • Metastatic Renal Cell Carcinoma Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2014*
  • Metastatic Renal Cell Carcinoma Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2014*
  • Proportion of Metastatic Renal Cell Carcinoma to Oncology Clinical Trials, G7 Countries (%), 2014*
  • Metastatic Renal Cell Carcinoma Therapeutics, G7 Countries, Clinical Trials by Phase, 2014*
  • Metastatic Renal Cell Carcinoma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014*
  • Proportion of Metastatic Renal Cell Carcinoma to Oncology Clinical Trials, E7 Countries (%), 2014*
  • Metastatic Renal Cell Carcinoma Therapeutics, E7 Countries, Clinical Trials by Phase, 2014*
  • Metastatic Renal Cell Carcinoma Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014*
  • Metastatic Renal Cell Carcinoma Therapeutics, Global, Clinical Trials by Phase (%), 2014*
  • Metastatic Renal Cell Carcinoma Therapeutics, Global, Clinical Trials In Progress by Phase, 2014*
  • Metastatic Renal Cell Carcinoma Therapeutics, Global, Clinical Trials by Trial Status, 2014*
  • Metastatic Renal Cell Carcinoma Therapeutics Clinical Trials, Global, by End Point Status, 2014*
  • Metastatic Renal Cell Carcinoma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013
  • Metastatic Renal Cell Carcinoma Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014*
  • Metastatic Renal Cell Carcinoma Therapeutics Clinical Trials, Global, Key Sponsors, 2014*
  • Metastatic Renal Cell Carcinoma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014*
  • Metastatic Renal Cell Carcinoma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014*
  • GlobalData Methodology
Back to Top